Johnson & Johnson Secures FDA Approval for Tecvayli and Darzalex Faspro Combo in Relapsed/Refractory Multiple Myeloma on March 06, 2026 Approved Darzalex Faspro JNJ Johnson & Johnson Multiple Myeloma Relapsing course Tecvayli United States Food and Drug Administration Unresponsive to Treatment +
J&J's Tecvayli and Darzalex Combo Wins FDA's Proactive National Priority Voucher for Relapsed/Refractory Multiple Myeloma on December 16, 2025 Asymmetric Septal Hypertrophy CNPV Darzalex J&J Multiple Myeloma National Priority Voucher Tecvayli United States Food and Drug Administration +